EP4091607A1 — Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics
Assigned to Karuna Therapeutics Inc · Expires 2022-11-23 · 3y expired
What this patent protects
Provided is a method of treating a central nervous system disorder in a patient in need thereof, the method comprising co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising an antipsychotic. In certain embodiments, a …
USPTO Abstract
Provided is a method of treating a central nervous system disorder in a patient in need thereof, the method comprising co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising an antipsychotic. In certain embodiments, a method of treating schizophrenia in a patient in need thereof is provided. For example, the method comprises co-administering a first composition comprising xanomeline and/or a salt thereof and a second composition comprising risperidone or aripiprazole. In certain embodiments, the first composition comprising xanomeline and/or a salt thereof further comprises an anticholinergic agent, such as a muscarinic antagonist.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.